Catalent Pharma Solutions announced two appointments to the management structure of its Development and Clinical Services division, to further support its global customer needs.
Somerset, N.J. – September 25, 2014 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced two appointments to the management structure of its Development and Clinical Services division, to further support its global customer needs. The move sees the creation of two new senior leadership roles to support drug development and clinical trial growth in the United States, Europe and Asia.
Mr. Paul Hegwood, currently VP Operations for the Clinical Supply Services offerings will assume the new role of VP Operations for the Development and Clinical Services division for the Americas and Asia-Pacific regions. Mr. Stuart Cryer, who is currently VP Operations for the Development and Analytical Solutions offerings, will become the new VP Operations for the Development and Clinical Services division for Europe and the Rest of World.
“These appointments are part of our strategic investment and growth strategy across our global network, especially for our fast growing Clinical Supply Services network, which comprises eight GMP facilities and over fifty depots across all continents,” commented Scott Houlton, President and CEO, Development and Clinical Services. “The move provides further regional customer focus, plus greater local regulatory expertise, and will facilitate faster execution to support our clients’ needs wherever they are in the world.”
Catalent currently supports the clinical trial supply needs of the top 25 pharmaceutical companies and more than 300 small innovators from all over the world. With facilities located in the US, European, and Asia/Pacific regions, and covering six continents, Catalent Clinical Supply Services has a robust network built around the most complete integrated service offerings for pharmaceuticals in clinical trial phases I-IV.
Paul Hegwood was named Vice President of Global Operational Excellence for Catalent in April 2011, following an extensive career leading multi-national teams in operations, business development and product engineering. He had previously held the position of VP of Global Operations for Stanadyne Corporation and has held various leadership positions at General Motors and its automotive electronics and technology company, Delphi. He holds an MBA from the University of Michigan and a BME from Kettering University. Mr. Hegwood is a trained specialist in Lean Manufacturing and is a certified Six Sigma Green Belt.
Mr. Cryer has a Bachelor of Pharmacy honors degree from Bath University and over 25 years’ experience in the pharmaceutical industry. He has worked for a broad range of pharmaceutical organizations including Pfizer, Abbott, GSK and Aptuit. He has held roles in formulation and development, technical support and operational management.
+44 (0)7580 041073
+44 (0) 7974 579202
Catalent Pharma Solutions is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com